MedTrace Logo

COG-UK Project Hospital-Onset COVID-19 Infections Study

NCT04405934 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2170

Last updated 2022-03-02

No results posted yet for this study

Summary

Hospitals are recognised to be a major risk for the spread of infections despite the availability of protective measures. Under normal circumstances, staff may acquire and transmit infections, but the health impact of within hospital infection is greatest in vulnerable patients. For the novel coronavirus that causes COVID-19, like recent outbreaks such as the SARS and Ebola virus, the risk of within hospital spread of infection presents an additional, significant health risk to healthcare workers.

Infection Prevention and Control (IPC) teams within hospitals engage in practices that minimise the number of infections acquired within hospital. This includes surveillance of infection spread, and proactively leading on training to clinical and other hospital teams.

There is now good evidence that genome sequencing of epidemic viruses such as that which causes COVID-19, together with standard IPC, more effectively reduces within hospital infection rates and may help identify the routes of transmission, than just existing IPC practice. It is proposed to evaluate the benefit of genome sequencing in this context, and whether rapid (24-48h) turnaround on the data to IPC teams has an impact on that level of benefit.

The study team will ask participating NHS hospitals to collect IPC information as per usual practice for a short time to establish data for comparison. Where patients are confirmed to have a COVID-19 infection thought to have been transmitted within hospital, their samples will be sequenced with data fed back to hospital teams during the intervention phase. A final phase without the intervention may take place for additional information on standard IPC practice when the COVID-19 outbreak is at a low level nationwide.

Conditions

  • Covid-19
  • Nosocomial Infection
  • Coronavirus
  • Coronavirus Infection
  • SARS-CoV 2

Interventions

OTHER

Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures

Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports

Sponsors & Collaborators

  • Public Health England

    collaborator OTHER_GOV

  • University College, London

    lead OTHER

Principal Investigators

  • Judith Breuer, MD · University College, London

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2021-04-26
Completion
2021-10-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405934 on ClinicalTrials.gov